Precision NanoSystems @ The BIO International Convention 2017

A key session opens up the challenges of delivering personalized genetic medicines

Visitors to the upcoming BIO International Convention in San Diego will have the opportunity to explore how key players in the industry are tackling the challenges of personalized genetic medicines. The hour-long session, hosted by Precision NanoSystems and moderated by the company’s COO and co-founder Euan Ramsay, will be held on June 22nd, from 9am, at the San Diego Convention Center, RM 6C. Speakers have been chosen for their specific focus in different stages of the clinical development process, and will talk about the challenges and possible solutions for genetic medicine development.

Arthur Tzianabos from Homology Medicines will begin the session by looking at genome editing from a viral vector perspective. Intellia’s Thomas Barnes will then discuss the company’s CRISPR/Cas9 genome editing technology, outlining how different drug delivery technologies may be suitable for different diseases. This will be followed by an explanation of how Gritstone Oncology is combining technologies to deliver personalized cancer vaccines from the company’s Karin Jooss. And finally, the audience will hear from Melinda Griffith from the Parker Institute, who will be describing the first CRISPR/Cas9 trial in the United States, and the regulatory and ethical challenges it has raised. The floor will then be opened up for a Q&A session with the panel.

Moderator Euan Ramsay said: “Precision NanoSystems is delighted to be organizing this exciting session, providing an exclusive opportunity to bring leading lights from across this fast-growing sector together to discuss the latest developments. We are very grateful to all of our speakers for agreeing to participate, and look forward to their presentations.”

To register for the session, entitled Will the challenges of delivering the personalized genetic medicines of tomorrow outweigh the promise of today, visit

To learn more about the event and Precision NanoSystems, visit

About Precision NanoSystems

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases. PNI’s NanoAssemblr™ Transfection Reagents use nanomedicine technology to deliver genetic materials in primary cells vitro and in vivo, enabling disease researchers to easily study gene function in high-value models of disease. PNI’s proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of nanoparticle formulations for delivery of nucleic acids, drug molecules, and diagnostic agents to cells and tissues in the body. PNI sells its products to leading pharmaceutical and biotechnology companies, and leading academic institutions in over 20 countries worldwide.

Back to news